Lu Xun, Wan Xiao-Wen
Department of Traditional Chinese Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University Suzhou 215008, Jiangsu, China.
Am J Transl Res. 2024 Jun 15;16(6):2358-2368. doi: 10.62347/GHOV4912. eCollection 2024.
To explore the mechanism of Qigui-Yishen decoction in delaying renal fibrosis in mice by regulating thrombin regulatory protein (Thrombomodulin, TM) and plasminogen activator inhibitor-1 (PAI-1) based on network pharmacology.
The active ingredients of Qigui Yishen decoction and their target molecules associated with chronic kidney disease (CKD) were retrieved from websites and databases, sorted out, and screened, and the possible targets of Qigui Yishen decoction for reducing CKD renal fibrosis were predicted and analyzed. Forty Institute of Cancer research (ICR) rats were used to establish a unilateral ureteral obstruction (UUO) model, and divided into several groups: sham operation group, model group, high concentration decoction group (1 g/mL), low concentration decoction group (0.46 g/mL), and benazepril group (0.1 g/mL). At the end of the experiment, the levels of serum creatinine (Scr) and blood urea nitrogen (BUN) were detected. Masson staining was used to observe changes in the renal interstitial fibrosis index. Immunohistochemistry and western blot were used to detect the expressions of TM, PAI-1, transforming growth factor-β1 (TGF-β1) and collagen I (Col I) in kidney tissues, and the differences between groups were compared.
Qigui Yishen decoction contains 42 effective ingredients such as sitosterol, mannitol, and quercetin, with 662 drug targets and 16154 disease targets. Analysis revealed 570 potential targets, including TM4SF19, PAIP1, TGF-β1, and Col I-AI. Compared to the sham operation group, all treatment groups exhibited increased Scr and BUN levels (P<0.05) and enhanced renal interstitial fibrosis (P<0.05) after UUO model establishment. Moreover, immunohistochemical results showed significant increases in PAI-1, TGF-β1, and Col I (all P<0.05), and a significant decrease in TM expression (P<0.05). Compared to the model group, the high concentration decoction group, low concentration decoction group and benazepril group had no significant difference in Scr and BUN values (>0.05), but the renal interstitial fibrosis index was lower (<0.05). Also, the relative expressions of PAI-1, TGF-β1 and Col I in the kidney tissue of mice were decreased, while the relative expression of TM was increased (<0.05).
Qigi Yishen decoction has the characteristics of multiple components and multiple targets, and can play a role in delaying renal fibrosis by regulating the expression of PAI-1, TGF-β1, Col I, and TM.
基于网络药理学探讨芪归益肾汤通过调节凝血酶调节蛋白(血栓调节蛋白,TM)和纤溶酶原激活物抑制剂-1(PAI-1)延缓小鼠肾纤维化的机制。
从网站和数据库中检索芪归益肾汤的活性成分及其与慢性肾脏病(CKD)相关的靶分子,进行整理和筛选,预测并分析芪归益肾汤减轻CKD肾纤维化的可能靶点。选用40只癌症研究所(ICR)大鼠建立单侧输尿管梗阻(UUO)模型,分为假手术组、模型组、高浓度汤剂组(1 g/mL)、低浓度汤剂组(0.46 g/mL)和苯那普利组(0.1 g/mL)。实验结束时,检测血清肌酐(Scr)和血尿素氮(BUN)水平。采用Masson染色观察肾间质纤维化指数变化。采用免疫组织化学和蛋白质印迹法检测肾组织中TM、PAI-1、转化生长因子-β1(TGF-β1)和I型胶原(Col I)的表达,并比较各组间差异。
芪归益肾汤含有42种有效成分,如甾醇、甘露醇、槲皮素等,有662个药物靶点和16154个疾病靶点。分析发现570个潜在靶点,包括TM4SF19、PAIP1、TGF-β1和Col I-AI。与假手术组相比,建立UUO模型后,各治疗组Scr和BUN水平均升高(P<0.05),肾间质纤维化加重(P<0.05)。此外,免疫组织化学结果显示PAI-1、TGF-β1和Col I均显著升高(均P<0.05),TM表达显著降低(P<0.05)。与模型组相比,高浓度汤剂组、低浓度汤剂组和苯那普利组Scr和BUN值差异无统计学意义(>0.05),但肾间质纤维化指数较低(<0.05)。小鼠肾组织中PAI-1、TGF-β1和Col I的相对表达降低,而TM的相对表达升高(<0.05)。
芪归益肾汤具有多成分、多靶点的特点,可通过调节PAI-1、TGF-β1、Col I和TM的表达发挥延缓肾纤维化的作用。